TENAX THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
TENAX THERAPEUTICS, INC. (TENX) reported Net Income (Loss) Available to Common Stockholders, Basic of $43.92 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-16.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2017-03-16
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2015-04-30 was $23.18M, a 42.37% decline year-over-year.
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2015-01-31 was -$2.87M.
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2014-10-31 was $4.05M, a 33.34% decline year-over-year.
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2014-07-31 was $2.17M, a 49.97% decline year-over-year.
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2016 was $43.92M.
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2015 was $14.08M, a 44.44% decline from fiscal 2014.
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2014 was $25.35M, a 144.32% increase from fiscal 2013.
- TENAX THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2013 was $10.37M, a 33.98% decline from fiscal 2012.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 8 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 545 month | Net Income (Loss) Available to Common Stockholders, Basic 554 month | Net Income (Loss) Available to Common Stockholders, Basic 557 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $43.92M 10-K · filed 2017-03-16 | |||||||||
| 2015-12-31 | $10.07M 10-K · filed 2017-03-16 | |||||||||
| 2015-04-30 | $23.18M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $20.31M derived: sum of 2 quarters · filed 2017-03-16 | $24.36M derived: sum of 3 quarters · filed 2017-03-16 | $14.08M 10-K · filed 2017-03-16 | ||||||
| 2015-01-31 | -$2.87M 10-Q · filed 2015-03-17 | $1.19M derived: sum of 2 quarters · filed 2015-03-17 | -$9.09M 10-Q · filed 2015-03-17 | $43.57M derived: sum of 4 quarters · filed 2017-03-16 | ||||||
| 2014-10-31 | $4.05M 10-Q · filed 2014-12-15 | $6.23M 10-Q · filed 2014-12-15 | $46.44M derived: sum of 3 quarters · filed 2017-03-16 | $41.99M derived: sum of 4 quarters · filed 2017-03-16 | ||||||
| 2014-07-31 | $2.17M 10-Q · filed 2014-09-15 | $42.39M derived: sum of 2 quarters · filed 2017-03-16 | $37.94M derived: sum of 3 quarters · filed 2017-03-16 | $44.02M derived: sum of 4 quarters · filed 2017-03-16 | ||||||
| 2014-04-30 | $40.22M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $35.77M derived: sum of 2 quarters · filed 2017-03-16 | $41.85M derived: sum of 3 quarters · filed 2017-03-16 | $25.35M 10-K · filed 2017-03-16 | ||||||
| 2014-01-31 | -$4.45M 10-Q · filed 2015-03-17 | $4.45M 10-Q · filed 2014-03-17 | $1.64M derived: sum of 2 quarters · filed 2015-03-17 | -$14.87M 10-Q · filed 2015-03-17 | $14.87M 10-Q · filed 2014-03-17 | $8.79M derived: sum of 4 quarters · filed 2016-03-14 | $133.32M 10-Q · filed 2014-03-17 | |||
| 2013-10-31 | $6.08M 10-Q · filed 2014-12-15 | $10.42M 10-Q · filed 2014-12-15 | $13.24M derived: sum of 3 quarters · filed 2016-03-14 | $15.65M derived: sum of 4 quarters · filed 2016-03-14 | $128.42M 10-Q · filed 2013-12-17 | |||||
| 2013-07-31 | $4.34M 10-Q · filed 2014-09-15 | $4.34M 10-Q · filed 2013-09-17 | $7.16M derived: sum of 2 quarters · filed 2016-03-14 | $9.57M derived: sum of 3 quarters · filed 2016-03-14 | $11.13M derived: sum of 4 quarters · filed 2016-03-14 | $122.34M 10-Q · filed 2013-09-17 | ||||
| 2013-04-30 | $2.82M derived: 10-KT 12 month − 10-Q 9 month · filed 2016-03-14 | $5.23M derived: sum of 2 quarters · filed 2016-03-14 | $6.79M derived: sum of 3 quarters · filed 2016-03-14 | $10.37M 10-KT · filed 2016-03-14 | $118.00M 10-K · filed 2013-06-26 | |||||
| 2013-01-31 | $2.41M 10-Q · filed 2014-03-17 | $3.97M derived: sum of 2 quarters · filed 2014-03-17 | $7.56M 10-Q · filed 2014-03-17 | |||||||
| 2012-10-31 | $1.56M 10-Q · filed 2013-12-17 | $5.14M 10-Q · filed 2013-12-17 | ||||||||
| 2012-07-31 | $3.59M 10-Q · filed 2013-09-17 | |||||||||
| 2012-04-30 | $15.71M 10-K · filed 2013-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |